Page last updated: 2024-12-05

dibutylnitrosamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

dibutylnitrosamine: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID13542
CHEMBL ID354920
CHEBI ID82356
SCHEMBL ID606730
MeSH IDM0059212

Synonyms (81)

Synonym
924-16-3
nitrosodibutylamine
n-butyl-n-nitroso-1-butamine
nitrosodi-n-butylamine
nsc-6830
wln: onn4&4
n-nitrosodibutylamine
di-n-butylnitrosamin
n-nitrosodi-n-butylamine
butylamine, n-nitrosodi-
dbna
n,n-dibutylnitrosoamine
nsc6830
di-n-butylnitrosoamine
ndba
dibutylamine, n-nitroso-
1-butanamine, n-butyl-n-nitroso-
n,n-di-n-butylnitrosamine
n-butyl-n-nitroso-1-butaneamine
dibutylnitrosoamine
di-n-butylnitrosamin [german]
dibutylnitrosamine
hsdb 5107
brn 1760378
rcra waste number u172
n,n-dibutylnitrosamine
einecs 213-101-1
n-butyl-n-nitroso-1-butanamine
rcra waste no. u172
di-n-butylnitrosamine
ccris 217
nsc 6830
n-butyl-n-nitrosobutan-1-amine
inchi=1/c8h18n2o/c1-3-5-7-10(9-11)8-6-4-2/h3-8h2,1-2h
n-nitrosodi-n-butylamine, analytical standard
n-nitroso-di-n-butylamine
n,n-dibutylnitrous amide
CHEMBL354920
chebi:82356 ,
N0375
n-dibutylnitrosamine
NCGC00248027-02
NCGC00248027-01
C19277
unii-8k8942wn31
8k8942wn31 ,
dtxcid101026
tox21_202334
NCGC00259883-01
dtxsid2021026 ,
NCGC00254330-01
cas-924-16-3
tox21_300425
FT-0633101
AKOS015902563
n,n-dibutylnitrosoamine [hsdb]
n-nitrosodibutylamine [usp-rs]
n-nitrosodi-n-butylamine [iarc]
SCHEMBL606730
n-di-n-butylnitrosamine
1219798-82-9
n-butyl-n-nitrosobutanamine
1,1-dibutyl-2-oxohydrazine #
n-di-n-butylnitrosoamine
YGJHZCLPZAZIHH-UHFFFAOYSA-N
1-butanamine,n-butyl-n-nitroso-
n-nitroso-di-n-butylamine 10 microg/ml in methanol
n-nitroso-di-n-butylamine 1000 microg/ml in methanol
Q22138402
HY-131113
CS-0128596
n-nitroso-di-n-butylamine-d18
D91692
dibutyl-nitroso-amine
n-nitrosodi-(n-butyl)amine
MS-22887
dibutyl(nitroso)amine
Z1255485634
EN300-7475958
n-nitroso-n-di-n-butylamine 0.1 mg/ml in methanol
n-nitroso-n-di-n-butylamine 1.0 mg/ml in methanol

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
"The aim of this study was to investigate the protective effect of isothiocyanates alone or in combination with vitamin C towards N-nitrosodibutylamine (NDBA) or N-nitrosopiperidine (NPIP)-induced oxidative DNA damage in the single cell gel electrophoresis (SCGE)/HepG2 assay."( Protective effects of isothiocyanates alone or in combination with vitamin C towards N-nitrosodibutylamine or N-nitrosopiperidine-induced oxidative DNA damage in the single-cell gel electrophoresis (SCGE)/HepG2 assay.
Arranz, N; García, A; Haza, AI; Morales, P; Rafter, J, 2008
)
0.35
"The aim of this study was to investigate the protective effects of organosulfur compounds (OSCs) alone or in combination with vitamin C towards N-nitrosopiperidine (NPIP) and N-nitrosodibutylamine (NDBA)-induced oxidative DNA damage in the single cell gel electrophoresis (SCGE)/HepG2 assay."( Organosulfur compounds alone or in combination with vitamin C protect towards N-nitrosopiperidine- and N-nitrosodibutylamine-induced oxidative DNA damage in HepG2 cells.
Arranz, N; Delgado, ME; García, A; Haza, AI; Morales, P; Rafter, J, 2008
)
0.35

Bioavailability

ExcerptReferenceRelevance
" However, the relationship of NB3CPA to NB4HBA was shifted in favor of NB4HBA, indicating a concentration and absorption rate dependency in the further metabolism of NB4HBA to NB3CPA."( Intestinal first-pass metabolism of nitrosamines. 4. Metabolism of N-nitrosodibutylamine in vascularly autoperfused jejunal and ileal loops of rats.
Feng, XC; Richter, E; Wiessler, M, 1990
)
0.28

Dosage Studied

ExcerptRelevanceReference
" at a dosage of 400 mg/kg body weight once a week for a maximum of 16 months to induce transitional cell carcinomas (TCC) of the bladder."( [Induction of urinary bladder urothelial cancers in the rabbit by dibutylnitrosamine with an artificial bladder calculus as cocarcinogen].
Bornhof, C; Giedl, J; Wolfrath, G, 1989
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
nitroso compoundCompounds having the nitroso group, -NO, attached to carbon, or to another element, most commonly nitrogen or oxygen.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency43.98780.002541.796015,848.9004AID1347397; AID1347398; AID1347399
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.41520.006038.004119,952.5996AID1159521
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency58.65240.003041.611522,387.1992AID1159552
retinoid X nuclear receptor alphaHomo sapiens (human)Potency16.88790.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency0.00430.001530.607315,848.9004AID1224842
pregnane X nuclear receptorHomo sapiens (human)Potency71.38390.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.58650.000229.305416,493.5996AID743079
activating transcription factor 6Homo sapiens (human)Potency21.87240.143427.612159.8106AID1159516
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency27.30600.000323.4451159.6830AID743066
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID226732The compound was modelled in silico for carcinogenic potency; + = Carcinogen1982Journal of medicinal chemistry, Jul, Volume: 25, Issue:7
Computer-assisted studies of structure-activity relationships of N-nitroso compounds using pattern recognition.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (100)

TimeframeStudies, This Drug (%)All Drugs %
pre-199054 (54.00)18.7374
1990's18 (18.00)18.2507
2000's11 (11.00)29.6817
2010's10 (10.00)24.3611
2020's7 (7.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.86

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.86 (24.57)
Research Supply Index4.65 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.86)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (1.92%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other102 (98.08%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]